If you work in a veterinary practice or in the pet industry or in a business that supplies goods or services to the industry and you have something to say - why not become a 'Guest Blogger'?
For more information click here to read our: Guidelines for Guest Bloggers
PharmAust is the absolute expert at helping treat dogs with aggressive lymphoma by developing a novel safe, effective, affordable oral treatment families can use at home.
Phase 2 clinical trials of PharmAust’s Monepantel drug showed that at the optimum dose, dogs with treatment naïve B Cell lymphoma achieved stable disease or better as assessed by the administering vets, and side effects were minimal.
Repurposing an existing safe, approved and widely used drug for new, targeted cancer treatments can greatly reduce the time required to provide new therapies to terminally ill patients.
The one thing that makes PharmAust different from its competitors is that it focuses on the discovery of novel uses for currently approved drugs.
PharmAust has discovered a potentially novel treatment for cancer in dogs and people. Monepantel represents a potential step change in canine lymphoma treatment versus costly and lengthy existing CHOP chemotherapy, which has significant side effects.
PharmAust hypothesises Monepantel works through an autophagy mechanism, inhibiting the mTOR protein which controls cell survival, and therefore can potentially have broad therapeutic applications.
For example, PharmAust is working with research partners to explore Monepantel’s potential action on the cancer-inducing HTLV-1 and COVID-19 respiratory viruses.
Phase 1 human trials of Monepantel to treat motor neuron disease, COVID-19 and a number of cancers are planned for 2023.
PhamAust is currently recruiting dogs across Australian trial sites focused on dose optimisation before commencing a Phase 3 trial for registration prior to seeking to bring Monepantel to market.
Site centres can be found at https://www.pharmaust.com/petdogtrial/ and for any further information, please contact Dr Roger Aston, Executive Chairman, PharmAust. Email: rogeraston@pharmaust.com Tel: (08) 9202 6814
Dr Roger Aston currently serves as Executive Chairman of PharmAust. Dr Aston brings more than 20 years experience in the pharmaceutical and healthcare industries in senior roles in the UK, Asia Pacific and Australia. He has had extensive experience on boards and as Chief Executive Officer of many private and publicly listed biotechnology companies. During his career, he has been closely involved in start-up companies and major pharmaceutical companies. Aspects of his experience include FDA and EU product registration, clinical trials, global licensing agreements, fundraising through private placements, and a network of contacts within the pharmaceutical, banking and stock broking sectors. Dr Aston holds a B.Sc. (Hons) and Ph.D. degrees from the University of Manchester from 1975 to 1981.
Connect with Roger:
Veterinary Wellness Retreats offers immersive wellness experiences in beautiful locations around the world. 1. We are absolute experts at... Veterinary Wellness Retreats are the absolute experts in helping veterinarians, technicians, and others in the veterinary...
